Prothena (NASDAQ:PRTA - Get Free Report) is set to post its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect Prothena to post earnings of ($1.18) per share for the quarter.
Prothena (NASDAQ:PRTA - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of ($1.01) by $2.23. The business had revenue of $132.01 million during the quarter, compared to analyst estimates of $10.73 million. Prothena had a negative net margin of 23.44% and a negative return on equity of 9.00%. Prothena's revenue for the quarter was up 3184.7% compared to the same quarter last year. During the same quarter last year, the business posted ($1.03) earnings per share. On average, analysts expect Prothena to post $-2 EPS for the current fiscal year and $-5 EPS for the next fiscal year.
Prothena Stock Performance
Shares of Prothena stock traded up $1.47 during midday trading on Wednesday, reaching $18.35. The company had a trading volume of 704,556 shares, compared to its average volume of 587,984. The stock has a fifty day simple moving average of $18.88 and a 200 day simple moving average of $20.54. Prothena has a 1-year low of $15.30 and a 1-year high of $41.54.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $84.00 price target on shares of Prothena in a report on Tuesday, October 1st. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Prothena in a report on Monday, September 30th. StockNews.com raised shares of Prothena from a "sell" rating to a "hold" rating in a report on Monday, August 12th. Royal Bank of Canada lowered their target price on shares of Prothena from $28.00 to $24.00 and set a "sector perform" rating for the company in a report on Friday, August 9th. Finally, Oppenheimer lowered their target price on shares of Prothena from $66.00 to $62.00 and set an "outperform" rating for the company in a report on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.86.
View Our Latest Stock Report on Prothena
About Prothena
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
See Also
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
